Fluoropharma Medical Inc · OTC:FPMI
Fluoropharma Medical — Investor Presentation (June 2012)
37 slides from Fluoropharma Medical's investor presentation, Jun 18, 2012
Slide 1: Enabling Personalized Medicine by Making the Invisible, Visible
Fluoro —— Er) Enabling Personalized Medicine by Making the Invisible, Visible.
Slide 2: Forward-Looking Statements
Fluoro Forward-Looking Statements Pharma ‘This presentation contains “forwarcooking statements’ within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, which are intended to be covered by
Slide 3: FluoroPharma At-a-Glance
FluoroPharma At-a-Glance Lalttelce} Pharma THE COMPANY CORE EXPERTISE THREE ACTIVE HEART IMAGING PROGRAMS. CLINICAL BENEFIT PATIENT MANAGEMENT Founded in 2003 in Boston with technology licensed from Massachusetts General Hospital Imaging drugs for diagnostic testing, BFPET a> Myocardial perfusion im
Slide 4: Investment Highlights
Lalttelce} Investment Highlights Pharma Proprietary products that support new technologies for personalized medicine ‘+ Next generation / firstin-class dlagnostic imaging + Helps determine the course of cardiac treatment Two Phase I-ready products with short study timelines, both directed to very la
Slide 5: Molecular Imaging value chain players
Molecular Imai Pharmaceutical Distribution A Molecular chert & Cardinal Health Covidien PET Philips Development Muttiple players in each value chain ‘www. FluoroPharma.com
Slide 6: Growing Market for Imaging Agents
ge, Growing Market for Imaging Agents Pharma x to exceed $15 billion by 2015 need Drug Marie + Global market exp. + Fueled by need for personalized medicine + Additional drivers include: + Growing volume of dlagnostic examinations Total ‘and equipment sales + Advanced imaging agents in development,
Slide 7: Personalized Medicine in Healthcare: Medicine Today
in Healthcare MEDICINE TODAY One treatment fits all - => still a guessing game ‘www. FluoroPharma.com
Slide 8: Personalized Diagnosis: Medicine Tomorrow
d Diagnosis MEDICINE TOMORROW must be personalized Right Treatment for the Personalized medicine begins with Right Patient at the the right diagnosis Right Time for the Right Outcome ¥ Before you can see it, Before the patient feels it, We can identify it ‘www. FluoroPharma.com
Slide 9: FluoroPharma Enables Personalized Diagnosis
Fluoro FluoroPharma Enables Personalized Diagnosis Pharma Imaging provides non-invasive tools with immediate personalized recommendations for treatment + Allows cirect visual evaluation o Method the efficacyof treatment 2 mm <10ms —Singlebubble nseto therapy tomake certain t continues to be appropri
Slide 10: Market Drivers for New PET Products
Fluoro Market Drivers for New PET Products Pharma Growth in PET Comprehensive adoption of early um diagnosis will improve utilization of .chnology z = + Atcapacity, more patients could be 3 diagnosed earlier leading to better patient. Q + + Earlier diagnosis benefitsthe health Fer SE system by minim
Slide 11: PET Imaging Roots are in Oncology
Lalttelce} PET Imaging Roots are in Oncology Pharma PET procedures by disease area (by amount tracer) 2800 2000 | Cardiology 2500 | and neurology 1000 strong growth ‘opportunities 500 6 _ — — 2008 2008, 2006 2008, Year WH Oncology Il Neurology Il Cardiology ‘www. FluoroPharma.com Saas FOR SIRNA
Slide 12: Cardiovascular Disease is the Next Big Opportunity
lar Disease is the Next Big Opportunity Pharma Total diagnostic radiopharmaceutical agents market: procedure volume forecasts by imaging procedure (U.S.) - a switch to PET Procedure 25) (citions) me on 204 (| caGR ‘07-09 PET (otal) 170% 6 SPECT (Cardiac) 7.3% s SPECT(Othe) 5.3% Total 7.6% 2004200520
Slide 13: Cardio Diagnostics
Lalttelce} e Cardio Diagnostics Pharma P tion** ‘www FluoroPharma.com etn 2042 mare sna ets)
Slide 14: Unmet Need for Better Imaging Methods
Lalttelce} Pharma Unmet Need for Better Imaging Methods FDA Warning in 2007 + Nephrogenic systemic fibrosis for Gadolinium-based contrast agents poromical fi FDA Warning in 2007 IMAGING + Deaths and serious cardiopulmonary reactions arising ‘rom marketed products None of hese area ‘molecular imaging
Slide 15: Making the Invisible, Visible
Fluoro Making the Invisible, Visible Pharma BFPET CardioPET VasoPET + For use in combination with * Modified fattyacid (MFA) with an» Avidly taken up by inflammato strese-testingin patients with ntemal block o prevent cells and rapialy aiviaing cols cAD metabolism + No uptakein stable plaque, + Pote
Slide 16: BFPET Clinical Use
Lalttelce} BFPET Clinical Use Pharma MYOCARDIAL PERFUSION IMAGING + Evaluate patients with known or suspected CAD for perfusion, wall motion and ejection fraction ‘+ Evaluate CAD in patients that are able to exercise CURRENT DIAGNOSTIC TEST + Perfusion imaging with SPECT tracers (MIBI, 1-201) or Rb-
Slide 17: BFPET Phase I Trial Findings
BFPET Phase | Trial Findings Pharma firm PETER ASE Ia Cory imaging prope Rapid extraction from blood Stable heart uptake overtime High target to background ratios A ee see ae nee Convenientimaging window within 30 in folow-upcinical and laboratory Dorey neers Bah + Whole body effectivedose:73.5 47.5
Slide 18: The BFPET Opportunity
Lalttelce} The BFPET Opportunity Pharma Est 5" Year Revenue $209 milion Market Est MktSie Est Share Myocardial perfusion imaging 410 mi ™% Peak procedure volume ~0.8 mil ‘www. FluoroPharma.com
Slide 19: CardioPET Clinical Use
Lalttelce} CardioPET Clinical Us Pharma CARDIAC VIABILITY ASSESSMENT * Identity patients that wil henefit from PC! or revascularization and guide intervention + Evaluate CAD in patients that cannot exercise CURRENT TREATMENT + Invasive coronary angiography CLINICAL NEED. + L3milion diagnostic angiog
Slide 20: CardioPET Phase I Trial Completed
CardioPET Phi Fatty acid analog that detects regions of metabolic insufficiency HASE | TRIAL COMPLETED (15 NHV and 6 CAD patients) + CatdioPET is safe with no AES detected + Clinical findings consistent with MPI SPECT + Quality of CardioPET images substantially ‘superior to MPI SPEcr A.15 minute sca
Slide 21: The CardioPET Opportunity
Lalttelce} The CardioPET Opportunity Pharma Projected CardioPET Scans. a :: Est. 5% Year Revenue 08 $220 milion or 06 Market ESLMAtSze ESLShare O° CAD diagnosis atrest 25 milion 15% 04 03 Cardiac viabilty — . assessment team we 02 Myocardial perfusion oa ati 20 milion 3% > | _| | Yearl Year3.—‘Year5
Slide 22: VasoPET Indications and Clinical Use
Lalttelce} \VasoPET Indicationsand Clinical Use Pharma EVALUATION OF + Patients with acute cardiac eventor stroke (risk of recurring event) + Therapy folowingacute cardiac eventor stroke (eg. Plavix lipid therapy, new treatments) CURRENT DIAGNOSTIC PRACTICE + Clinical symptoms; severalimaging agents
Slide 23: Inflamed Atherosclerotic Plaque
Fluoro | Inflamed Atherosclerotic Plaque Pharma WHY INFLAMMATION IMAC + Diagnosis before symptoms occur + Crucial role at all stages of atherosclerosis + May aid drug development DEVELOPMENT STATUS + Preclinical testing compl ND preparation ongoing + Plan to intiate Phase proof of principle trial at
Slide 24: The VasoPET Opportunity
Lalttelce} The VasoPET Opportunity Pharma Est. 5 Year Revenue 213 miton Maske Est Mite Et Shae Soeeansir ——somtion 0.6% Foewspaterhest — Sauen 106 Folowupaterstoke —O8milon 20% Peak procedure volume ~0.6 million ‘www. FluoroPharma.com
Slide 25: Targets Greatest Areas for Cost Reduction
Lalttelce} Targets Greatest Areas for Cost Reduction Pharma Therapeutics aimed to prevent and best treat disease related to diabetes, obesity and heart disease hold greatest promise Pharmaceuticals enabling personalized, outcomesdriven medicine offer greatest route to reducing the overall costs of h
Slide 26: Experienced Management Team and Advisors
Lalttelce} Experienced Management Team and Advisors Pharma Tis Spor Presient. CEO feotcae execute wih 15 years medalist experience + Former secures araist at JP- Morgan and Celt Suse cove the medal device and botecinogy + Previous ed te rucearcaranog portlet an PET rew procut oppotunty pots (Amersha
Slide 27: Growth Strategy / Near-Term Milestones
Lalttelce} Growth Strategy / Near-Term Milestones Pharma Capitalize on multiple cardiovascular molecular imaging agents for PET * Cardiac viability assessment + Myocardial perfusion imaging + Inflamed atherosclerotic plaque imaging Address unmet needs in cardiovascular diagnostics by providing * Dia
Slide 28: Slide 28
Slide 29: The cycle of classic medicine is reactive medical care
Lalttelce} The cycle of classic medicine is reactive medical care Pharma Reactive Medical Care Switch Dace Seventy Diagnosis Time Diagnose Disease: Treat Symptoms; Costly, Trial and Error Treatment ae Fasano Os
Slide 30: Shifting to outcomes focused personalized medicine increases efficiency
Lalttelce} hifting to outcomes focused personaliz increases efficiency Pharma Efficient Medical Care Right Drug Dace Seventy Prognosis Health Management; Molecular Screening: Early Detection Rapid Effective Treatment; Improved Quality of Care ‘www. FluoroPharma.com
Slide 31: Cardiovascular Disease
Lalttelce} Cardiovascular Disease Pharma Reactive Medical Care Switch Dace Seventy Diagnosis Time Diagnose Disease: Treat Symptoms; Costly, Trial and Error Treatment ae Faasaises Vedas Coy
Slide 32: Cardiovascular Disease
Cardiovascular Disease KEY FACTS - US AND WW leglected Global Epidemic” + 16.7M deaths WW: 1/3 of all deaths, 78% from iow./ middle income countries + 1/3 of deaths in China, ¥2in Europe + 2.4M deaths US: top cause (2. KEY UNMET NEE 1S + CAD: Get closer tothe disease source - Eatly detection & appro
Slide 33: Vulnerable Plaque
Vulnerable Plaque Individual Plaques Plaque Imaging ‘www. FluoroPharma.com
Slide 34: AD Statistics
AD Statistics Lalttelce} Pharma 4th leading cause of death after CHD, cancer and stroke. 25M people estimated to have AD globally (2000). + Incidence - 4.5M globally (2000). + By 2030, 63M people will have AD at current rates. + National cost of AD care is. $1008 annually in the US. AD Pathological
Slide 35: Regulatory Strategy - CardioPET
Lalttelce} Regulatory Strategy -CardioPET Pharma US FDA requirements for NDA: safety and efficacy Phasela + Safety, dosimetry and pharmacokinetics; imaging protocol in (Completed) healthy volunteers (15 NHV); single center Phaselb + Safety, pharmacokinetics and comparison to MPL in small (Completed)
Slide 36: Outcomes partnerships drive clinical trial endpoints
Outcomes partnerships drive clinical trial endpoints Economic pressures PAST FUTURE Fragmen a ee ee ee ee ted,non- systemsof (0 Gorventonat Sole practitioners Quality patient are ~ ‘anecdotal reputation ‘among patents a e003 provider Provider Imaging drug is a resource perspectveon Rx JR tantees al
Slide 37: Thank you for listening!
Fluoro —— Er) Thank you for listening!
FluoroPharma Medical — Investor Presentation (June 2012) on 6ix